Literature reviews

To download literature reviews on Neutropenia, click on the following articles:


2009

Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer [153 KB]
Stokes ME, Muehlenbein CE, et al. J Manag Care Pharm 2009; 15(8):669-82
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. [42 KB]
Chirivella I, et al. Breast Cancer Res Treat. 2009;114(3):479-84

Impact of chemotherapy dose intensity on cancer patient outcomes. [42 KB]
Lyman GH, J Nat Compr Canc Netw. 2009;7:99-108

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. [31 KB]
Sharma R, et al. BMC Cancer. 2009;9:153

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. [39 KB]
Shayne M, et al. Cancer. 2009;15:5319-28

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis. [66 KB]
von Minckwitz G, et al. Eur J Cancer. 2009;45(4):608-17

Risk of hospitalisation for neutropenic complications of chemotherapy in patients with primary solid tumours receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. [34 KB]
Weycker D, et al. Clin Ther. 2009;31(5):1069-81
Last update: 2011-10-17

The content of this website is intended for healthcare professionals.
All content is approved by the INC-EU study group members.

The INC-EU and this website are supported by an educational grant from

Amgen (Europe) GmbH.